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UbiquitinationHypophosphatasia (HPP), a rare genetic disease characterized by reduced serum alkaline phosphatase (ALP)
activity and failure in bone and tooth mineralization, is caused by mutations in tissue-nonspeciﬁc ALP
(TNSALP) gene. Two missense mutations (C201Y and C489S, standardized nomenclature) of TNSALP, in-
volved in intra-chain disulﬁde bonds, were reported in patients diagnosed with perinatal HPP (Taillandier
A. et al. Hum. Mutat. 13 (1999) 171–172, Hum. Mutat. 15 (2000) 293). To investigate the role of the disulﬁde
bond in TNSALP, we expressed TNSALP (C201Y) and TNSALP (C489S) in COS-1 cells transiently. Compared
with the wild-type enzyme [TNSALP (W)], both the TNSALP mutants exhibited a diminished ALP activity in
the cells, where a 66 kDa immature form was predominant with a marginal amount of a 80 kDa mature
form of TNSALP. Detailed studies on Tet-On CHO established cell line expressing TNSALP (W) or TNSALP
(C201Y) showed that the 66 kDa form of TNSALP (C201Y) exists as a monomer in contrast to a dimer of
TNSALP (W). Only a small fraction of the TNSALP (C201Y) reached cell surface as the 80 kDa mature form,
though most of the 66 kDa formwas found to be endo-β-N-acetylglucosaminidase H sensitive and rapidly de-
graded in proteasome following polyubiquitination. Collectively, these results indicate not only that the
intra-subunit disulﬁde bonds are crucial for TNSALP to properly fold and assemble into the dimeric enzyme,
but also that the development of HPP associated with TNSALP (C201Y) or TNSALP (C489S) is attributed to de-
creased cell surface appearance of the functional enzyme.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Hypophosphatasia (HPP) is an inborn error of metabolism charac-
terized by defective mineralization of bone and tooth [1,2]. Reduced
levels of serum alkaline phosphatase (ALP) activity are a biochemical
hallmark [1,2]. It is well established that development of this genetic
disease is ascribed to various mutations in the tissue-nonspeciﬁculbecco's modiﬁed minimum
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rights reserved.alkaline phosphatase (TNSALP) gene [1–4]. HPP is clinically classiﬁed
into ﬁve major categories depending on the age at diagnosis: perina-
tal, infantile, childhood, adult and odonto forms. Generally, severe
HPP (perinatal and infantile forms) is transmitted in an autosomal re-
cessive pattern, while mild HPP (childhood, adult and odonto forms)
is transmitted in a recessive or dominant way.
Inorganic pyrophosphate, phosphoethanolamine and pyridoxal-
5′-phosphate are natural substrates of TNSALP in vivo as these
phosphocompounds have elevated levels in the serum or urine of
HPP patients and TNSALP-deﬁcient mice [3,5–8]. Among them, inor-
ganic pyrophosphate acts as a negative regulator of bio-
mineralization [3,5]. Hydroxyapatite starts crystallizing in the matrix
vesicle and then the crystals grow out of the matrix vesicle mem-
brane into the bone matrix. TNSALP molecules on the matrix vesicle
are capable of hydrolyzing pyrophosphate to phosphate at the site
of mineralization, thus accelerating hydroxyapatite growth. On the
other hand, the mineralization can be suppressed by the accumula-
tion of pyrophosphate in HPP patients as the number and catalytic
property of the TNSALP molecule expressed on the matrix vesicle
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gene [1–4].
TNSALP is a glycoprotein and synthesized as a 66 kDa form with
high-mannose type N-linked oligosaccharides in the endoplasmic re-
ticulum (ER), processed to a 80 kDa mature form with complex-type
oligosaccharides and ﬁnally anchored to the cell membrane via glyco-
sylphosphatidylinositol (GPI) [9,10]. Functional TNSALP is a homodi-
mer linked non-covalently [11–13]. To date, a total of 254 TNSALP
mutations have been reported worldwide as of December 2011 and
the most frequent mutation type is missense one (76% of all muta-
tions) (http//www.sesep.uvsq.fr/03_hypo_mutations.php). Missense
mutations are thought as a kind of natural site-directed mutagenesis
experiments and an attempt was made to map eachmisspelled amino
acid residue on the 3D model of TNSALP to gain insight to molecular
basis of HPP [13]. TNSALP (C201Y) and TNSALP (C489S) were
reported in perinatal HPP patients (according to standardized no-
menclature, where the ATG initiator codon is numbered as 1)
[14,15]. As cysteine residues at positions 201 and 489 covalently
link to 139 and 497, respectively, in the same subunit, it is quite rea-
sonable to assume that two disulﬁde bonds (C-139–C-201, C-489–C-
497) play crucial roles for TNSALP to adopt proper folding and the
correct dimer structure [13]. However, the effects of disrupting
intra-chain disulﬁde bonds on TNSALP molecule have not been inves-
tigated in detail so far. Here we report that TNSALP (C201Y) and
TNSALP (C489S) largely lose their enzyme activity probably because
most of them fail to assemble into the functional dimeric structure
and undergo endoplasmic (ER) associated degradation.
2. Materials and methods
2.1. Materials
Our reagents were obtained from the following commercial
sources. Enhanced chemiluminescence plus (ECL) western blotting
detection reagents, peroxidase-conjugated donkey anti-(rabbit IgG),
peroxidase-conjugated sheep anti-(mouse IgG) and Protein A-
Sepharose CL-4B were from Amersham Pharmacia Biotech (Arlington
Heights, IL, USA); Rhodamine-conjugated sheep anti-(rabbit IgG)
from Cappel (Solon, Ohio, USA.); G418 and pansorbin from Calbio-
chem (La Jolla, CA, USA); fetal bovine serum, Opti-MEM and Lipofec-
tamine Plus Reagent from Invitrogen (Carlsbad, CA, USA);
QuikChange lightning Site-Directed Mutagenesis Kit from Stratagene
(La Jolla, CA, USA); Peptide: N-glycosidase F (Flavobacteriummeningo-
septicum, PNGase F), from New England Biolabs (Beverly, MA, USA);
Neuraminidase (Arthrobacter ureafaciens) from Roche (Indianapolis,
IN, USA): endo-β-N-acetylglucosaminidase H (Streptomyces griseus,
Endo H) from Seikagaku Kogyo (Kyoto, Japan); phosphatidylinositol-
speciﬁc phospholipase C (Bacillus cereus, PI-PLC) from BIOMOL Inter-
national, L.P. (PlymouthMeeting, PA, USA); aprotinin, baker's yeast al-
cohol dehydrogenase, bovine serum albumin, cycloheximide,
doxycycline and N-acetyl-L-leucinyl-L-leucinyl-L-norleucinal (LLnL)
from Sigma Chemical Co. (St. Louis, MO, USA); High Speed Plasmid
Midi-kit from Qiagen (Hilden, Germany); pTRE2-hygro and BD®
CHO-K1 Tet (tetracycline)-On cell line and Tet system approved
Fetal bovine serum from Clontech (Palo Alto, CA, USA); antipain, chy-
mostatin, elastatinal, lactacystin, leupeptin and pepstatin A from Pro-
tein Institute INC (Osaka, Japan); Anti-Multi Ubiquitin from MBL
(Nagoya, Japan); bovine liver catalase, cycloheximide and hygromycin
B fromWako Pure Chemicals (Tokyo, Japan), antiserum against recom-
binant human TNSALP was raised in rabbits as described previously
[16].
2.2. Plasmids and transfection
The pSG5 encoding TNSALP (W) was constructed as described
previously [9]. Mutations were introduced at speciﬁc sites usingQuikChange lightning Site-Directed Mutagenesis Kit essentially
according to the manufacturer's protocol. Oligonucleotides used are:
TNSALP (C201Y), 5′-TTGAGCCAGGGCTATAAGGACATCGCCTACC-3′
and 5′-GGTAGGCGATGTCCTTATAGCCCTGGCTCAA-3′; TNSALP (C489Y),
5′-TGGCGTATGCAGCCTCCATCGGGGCCAACCT-3′ and 5′-AGGTTGGCCCC-
GATGGAGGCTGCATACGCCA-3′. The full coding sequence of each
TNSALP mutant was veriﬁed by DNA sequence analysis. The cDNA
encoding TNSALP (C201Y) was further subcloned into pTRE2-hygro to
establish stable cell lines. Transfection and screening of stable cell
lineswere performed essentially according to themanufacturer's proto-
col. Tet-On cells, which successfully expressed the mutant TNSALP in
the presence of doxycycline, but not in its absence, were identiﬁed
using immunoﬂuorescence. Tet-On CHO K1 cells expressing TNSALP
(W) were established previously [10]. Established Tet-On cells were
cultured and passaged in the absence of doxycycline until they were
used for experiments. For western blotting or immunoﬂuorescence
studies, the cells were cultured in the presence of 1 μg/ml doxycycline
for 24 h before being used. For transient expression, COS-1 cells [(0.8–
1.0)×105 cells/35-mm dish] were transfected with 0.5 μg of each plas-
mid using Lipofectamine Plus according to the manufacturer's protocol
as described previously [10,12] and the transfected cells were incubated
for 24 h in 5% CO2/95% air incubator before use. COS-1 cells were cul-
tured in Dulbecco's modiﬁed Eagle's minimum essential medium
(DMEM) supplemented with 10% fetal bovine serum [9,10].2.3. Chase experiments
To test if TNSALP (C201Y) is degraded when expressed in Tet-On
CHO cells, chase experiments were carried out. Cells in 35-mm dishes
were washed three times with Opti-MEM and incubated with 1 ml of
Opti-MEM for various periods. For chase experiments, cycloheximide,
an inhibitor of protein synthesis was added at the start of the experi-
ments (a ﬁnal concentration of 100 μM). Proteasomal inhibitors were
added 30 min before the addition of cycloheximide and present
throughout the experiments (ﬁnal concentration of 50 μM). Cyclohexi-
mide and lactacystin were dissolved in dH2O (100mM stock and 1 mM
stock, respectively) and LLnL was dissolved in dimethylsulfoxide
(50 mM stock) and kept at −20 °C until use. At indicated times, each
medium was removed and the cells in the dish were washed three
times with phosphate-buffered saline.2.4. Western blotting
To examine molecular species of TNSALP, the cells expressing
TNSALP mutant proteins were analyzed by western blotting. The
cells were scraped and collected by centrifugation. The cell pellets
were homogenized with 100–200 μl of 10 mM Tris/HCl (pH 7.2)
using a sonicator. Aliquots of homogenates were directly analyzed
by SDS-PAGE, followed by western blotting. For immunoprecipitation
(IP)-western blotting experiments, the cells were lysed in 0.5 ml of
lysis buffer [1% (w/v) Triton X-100/0.5% (w/v) sodium deoxycholate/
0.05% (w/v) SDS in phosphate-buffered saline]. A protease inhibitor
cocktail (antipain, aprotinin, chymostatin, elastatinal, leupeptin,
pepstatin A) was added to the cell lysates. The lysates were incubat-
ed for 20 min at 37 °C to extract TNSALP from a cold-insoluble mem-
brane fraction. The lysates were subjected to immunoisolation as
described previously [17,18]. The immune complexes/Protein A
beads were boiled in the presence of 1% (v/v) 2-mercaptoethanol,
and then analyzed by SDS/PAGE [9% (w/v) gels], followed by electric
transfer. The membrane was sequentially incubated with anti-Multi
Ubiquitin (1:1000) and peroxidase conjugated Goat-anti-mouse IgG
(1:4000). After treated with ECL Plus reagents, protein bands on the
membrane were detected using LAS 4000 mini (GE Healthcare,
Tokyo, Japan).
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To characterize the oligosaccharide chains attached to TNSALP
molecules, the cells expressing TNSALP were treated with various gly-
cosidases. Tet-On cells expressing TNSALP (W) or TNSALP (C201Y9)
were homogenized in 5 mM Tris/HCl (pH 7.2) and used for glycosi-
dase digestions. For PNGase F, the cell homogenates were incubated
with 5000 units/ml of the enzyme in the presence of 0.4% TX-100 at
37 °C essentially according to the manufacturer's protocol. The ho-
mogenates were also incubated with neuraminidase (ﬁnal concentra-
tion of 0.2 U/ml) or Endo H (ﬁnal concentration of 0.1 U/ml) in the
presence of 0.4% Triton X-100 and the protease inhibitor cocktail at
37 °C. After 16 h each sample was subjected to trichloroacetic acid
precipitation (ﬁnal concentration of 10%) with 15 μg of alcohol dehy-
drogenase as carrier prior to SDS-PAGE.
2.6. Miscellaneous procedures
To assess the cell surface appearance, PI-PLC digestion was carried
out as described previously [17,18] with a slight modiﬁcation; instead
of immunoprecipitation, media containing soluble TNSALP wereFig. 1. Enzyme activity of TNSALP mutants in the homogenates of transfected COS-1cells. (A
(W), TNSALP (C201Y), TNSALP (C489S) or TNSALP (C201Y/C489S) and their homogenates w
TNSALP (W), TNSALP (C201Y) or TNSALP (C489Y)were stained for ALP for 10 min at room temp
a very low ALP compared with TNSALP (W).subjected to trichloroacetic acid precipitation (ﬁnal concentration of
10%) prior to SDS-PAGE. Sucrose-density-gradient centrifugation
was performed to analyze the assembly of TNSALP as described pre-
viously [10,11]. Cytochemical staining and immunoﬂuorescence for
ALP were performed as described previously [18,19]. Protein and ALP
assays were carried out as described previously [17,18]. One unit of
ALP activity is deﬁned as nmoles of p-nitrophenylphosphate hydrolyzed
per min at 37 °C. A 3D model of TNSALP was constructed using PYMOL
as described previously [12].
3. Results
3.1. Transient expression of TNSALP (C201Y) and TNSALP (C489S) in
COS-1 cells
To examine the effects of two different missense mutations on
TNSALP molecule, which are involved in the formation of intra-
chain disulﬁde bond [9], we transfected plasmids encoding these
TNSALP mutants into COS-1 cells. As expected from their association
with perinatal HPP, both TNSALP (C201Y) and TNSALP (C489S)
showed a diminished ALP activity compared with wild-type enzyme) The cells were untransfected (control) or transfected with plasmids encoding TNSALP
ere assayed for ALP and expressed in units/mg protein (y-axis). (B) The cells expressing
erature. Control: untransfected cells. TNSALP (C201Y) and TNSALP (C489S) exhibited only
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sing TNSALP (C201Y, C489S), though this is not a natural occurring
mutation. These results indicate that the intra-chain disulﬁde bond
is crucial for TNSALP to become a functional enzyme. In compatible
with this result, both TNSALP (C201Y) and TNSALP (C489S) gave
much weaker ALP reaction products on the cell surface than did
TNSALP (W) (Fig. 1B). As reported previously [9,10], TNSALP enzyme
is synthesized as a 66 kDa immature form with high mannose-type
oligosaccharides and undergoes N-glycan processing to become a
80 kDa mature form with complex-type oligosaccharide chains during
the migration from ER to plasma membrane by way of the Golgi appa-
ratus. As shown in Fig. 2, the transfected cells were analyzed bywestern
blotting under reducing and non-reducing conditions using anti-
TNSALP antibody. In the cells expressing TNSALP (W) we observed
both the 66 kDa and the 80 kDa forms. However, the 80 kDa band was
barely detected in the cells expressing the TNSALP mutants, suggesting
that these TNSALP mutants largely fail to become the mature form.
Moreover, a large fraction of the 66 kDa TNSALP mutant proteins was
found to form a disulﬁde-linked high-molecular-mass aggregate
revealed under the non-reducing condition. This aggregation of the
66 kDa form occurred even in the cells expressing TNSALP (W), albeit
a lesser amount, resulting in a higher ratio of the 80 kDa band to the
66 kDa one under the non-reducing condition. The aggregation is partly
due to an excess amount of the protein produced in the transiently
transfected COS-1 cells, where a signiﬁcant amount of TNSALPmolecule
remained unmodiﬁed by glycosylphosphatidylinositol (GPI) and tends
to aggregate [20].
3.2. Established cell line expressing TNSALP (C201Y)
As both the mutants showed similar molecular properties in the
transient expression system (Figs. 1,2), we focused on TNSALP
(C201Y) and analyzed it more in detail. To start with, we established
Tet-On CHO K1 cell line, which induces the synthesis of this mutant
protein in response to the addition of doxycycline, tetracycline ana-
logue. The advantage of this system is that once synthesized the
66 kDa immature form of TNSALP is almost completely converted to
the 80 kDa mature form [10,12]. Tet-On cells expressing TNSALPFig. 2. Western blotting of transiently transfected COS-1 cell. The homogenates were
prepared from the cells expressing TNSALP (W), TNSALP (C201Y), T NSALP (C489S)
or TNSALP (C201Y/C489S) and analyzed by western blotting under a reducing or
non-reducing condition. An arrowhead indicates the top of the gel. Contrast with
TNSALP (W), the 80 kDa mature band was barely detectable in the cells expressing
the TNSALP mutants.(C201Y) showed only a negligible activity compared with those
expressing TNSALP (W), further conﬁrming that the C-122-C-201 di-
sulﬁde bond is essential for structural organization of TNSALP
(Fig. 3A). Unlike transiently transfected cells, the 80 kDa form was a
major molecular species in Tet-On cells expressing TNSALP (W) and
no high-molecular-mass aggregates were found under the non-
reducing condition (Fig. 3B). In contrast, the 66 kDa form was pre-
dominant in the cells expressing TNSALP (C201Y) with a trace
amount of smear disulﬁde linked high-molecular-mass bands when
analyzed under the non-reducing condition.
3.3. Characterization of TNSALP (C201Y)
TNSALP molecule has ﬁve consensus sites for N-linked oligosac-
charide chains and at least three of them are glycosylated when
expressed in COS-1 cells [9]. In order to characterize both the
80 kDa form of TNSALP (W) and 66 kDa form of TNSALP (C201Y), gly-
cosidase treatments were performed (Fig. 4A). The 80 kDa form was
sensitive to neuraminidase, but not to Endo H, whereas the 66 kDa
form was sensitive to Endo H, but not to neuraminidase. As glycopro-
teins acquire Endo H-resistance and terminal sugars such as galactose
and sialic acid during the passage across the Golgi apparatus, it is like-
ly that the 66 kDa form of TNSALP (C201Y) is retained in the ER.
A small fraction of TNSALP (C201Y) appeared on the cell surface in
transiently transfected cells (Fig. 1B). To ascertain whether TNSALPFig. 3. Established cell line expressing TNSALP (C201Y). Tet-on CHO K1 cells expressing
TNSALP (W) or TNSALP (C201Y) were incubated in the presence of 1 μg/ml of doxycy-
cline for 24 h. (A) The homogenates were assayed for ALP and expressed in units/mg
protein (y-axis), control: Tet-On CHO cells not expressing the TNSALP molecule. In
(B) the homogenates were analyzed by western blotting using anti-TNSALP antibody
under reducing and non-reducing conditions. Only a weak ALP activity was observed
in the Tet-On cells expressing TNSALP (C201Y) with the 66 kDa immature form.
Fig. 4. Characterization of the TNSALP (C201Y) molecule. In (A), the homogenates
from the established cell lines expressing TNSALP (W) or TNSALP (C201Y) were incu-
bated in the absence (lanes 1, 5) or presence of neuraminidase (lanes 2, 6), endo-β-N-
acetylglucosaminidase H (lanes 3, 7) or PNGase F (lanes 4, 8) for 16 h at 37 °C. The re-
action mixtures were subjected to trichloroacetic acid precipitation and analyzed by
western blotting under a reducing condition. In (B), Tet-On cells expressing TNSALP
(W) or TNSALP (C201Y) were incubated in the absence (lanes 1, 3, 5, 7) or presence
(2, 4, 6, 8) of PI-PLC (5 U/ml) at 37 °C for 1 h. The media were removed for trichloroa-
cetic acid precipitation (Med) and cells were homogenized (Cell), followed by western
blotting. In contrast to the 80 kDa mature form, the 66 kDa form was attached with
high mannose-type oligosaccharides as assessed by endo-β-N-acetylglucosaminidase
H and neuraminidase digestions.
Fig. 5. Sucrose-density-gradient centrifugation. The established cells expressing
TNSALP (W) or TNSALP (C201Y) were dissolved in the lysis buffer and incubated for
20 min at 37 °C. Then, each lysate was loaded on the top of a linear sucrose gradient
[5%–35% (w/w)] and centrifuged at 45,000 rev/min (163,000 gav) for 18 h. Each
400 μl fraction was collected from the top and analyzed by western blotting. A mixture
of alcohol dehydrogenase (125 kDa, a), bovine serum albumin (68 kDa, b) and catalase
(250 kDa, c) was centrifuged in a separate tube. Arrows indicate the positions of frac-
tion 7 (upper panel) and fraction 5 (bottom panel). TNSALP (C201Y) was present as
a monomer, in contrast to the dimeric form of TNSALP (W) as judged by sucrose-
density-gradient centrifugation.
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either TNSALP (W) or TNSALP (C201Y) were digested with
phosphatidylinositol-speciﬁc phospholipase C (PI-PLC) (Fig. 4), which
speciﬁcally cleaves the GPI moiety of TNSALP molecule [21,22]. In con-
trast to the TNSALP (W) (Fig. 4, lane 6), only a very faint 80 kDa band
of the mutant protein was detected in the medium (Fig. 4, lane 8), sug-
gesting that a small amount of TNSALP (C201Y) gains access to and is
anchored to the outer leaﬂet of plasmamembrane via a GPI in the estab-
lished cell line. Immunoﬂuorescence also conﬁrmed the cell surface ap-
pearance of this mutant protein in the established cell (data not
shown).
3.4. Dimerization
TNSALP (W) adopts the dimeric structure, which is linked non-
covalently [13].
Fig. 5 shows the sucrose-density-gradient centrifugation of the
cell homogenates expressing TNSALP (W) or TNSALP (C201Y).
TNSALP (W) appeared mostly in fraction 7, where alcohol dehydroge-
nase (125 kDa) was recovered, indicating that TNSALP (W) forms a
dimer. In contrast, a major part of TNSALP (C201Y) migrated at the
position of bovine serum albumin (69 kDa) in the gradient, pointing
to the monomeric status of the mutant protein. The distribution ofALP activity well overlapped with that of TNSALP (W) (highest in
fraction 7), while no activities were detected in the fractions of
TNSALP (201Y) (data not shown).3.5. Degradation by proteasome and polyubiquitination
Cells expressing TNSALP (C201Y) were chased after the addition
of cycloheximide, a protein synthesis inhibitor, as shown in Fig. 6A.
At indicated times the amount of this mutant was assessed by west-
ern blotting. The mutant protein was degraded rapidly. At 3 h-chase
time, the 66 kDa form was barely detectable in the cells. However,
this degradation was signiﬁcantly delayed in the presence of LLnL, a
proteasome inhibitor. Lactacystin, a speciﬁc proteasomal inhibitor,
strongly suppressed the degradation of the mutant protein, further
conﬁrming that proteasome is involved in the degradation of the
66 kDa form of this mutant protein. Misfolded and incorrectly assem-
bled proteins are often destroyed in the endoplasmic associated deg-
radation [23]. Besides, many of these proteins are known to be
polyubiquitinated prior to destruction. This was the case for TNSALP
(C201Y). We incubated the cells in the absence or presence of the
proteasomal inhibitor for 6 h and then aliquots of the cell homoge-
nates were directly analyzed with western blotting (Fig. 6B). In-
creased amounts of the mutant protein were observed in the cells
incubated either with LLnL or with lactacystin. Each residual homog-
enate was further subjected to immunoprecipitation (IP)-western
blotting procedure using anti-multi ubiquitin antibody, which recognizes
polyubiquitin chain rather than ubiquitin monomer. In the presence of
proteasomal inhibitor, especially lactacystin, we observed a strong
polyubiquitin signal.
Taken together, most of TNSALP (C201Y) failed to assemble into
the functional dimeric structure and instead of being ferried to the
Fig. 6. Degradation of TNSALP (C201Y). In (A), the established cells expressing TNSALP
(C201Y) were chased in the presence of 100 μM cycloheximide with or without 50 μM
LLnL or 50 μM lactacystin. The cells were homogenized and analyzed by western blot-
ting with anti-TNSALP antibody. In (B), the established cells expressing TNSALP
(C201Y) were incubated with or without 50 μM LLnL or 50 μM lactacystin for 6 h.
One twentieth of each cell homogenate was directly analyzed using anti-TNSALP anti-
body. For IP-western, the residual homogenate was dissolved in the lysis buffer and
subjected to immunoprecipitation using anti-TNSALP antibody. The immune-
complexes were processed for western blotting using anti-multi ubiquitin antibody.
TNSALP (C201Y) was rapidly declined in intensity and this degradation was strongly
inhibited by proteasomal inhibitors. The result suggests the involvement of protea-
some in the degradation process.
Fig. 7. 3D image of human TNSALP. Image presentation was carried out using PYMOL.
Cysteine residues (at positions of 119, 139, 201, 489 and 497) are shown only in one
subunit. C201 and C489 are disulﬁde-bonded to C139 and C497, respectively, to form
the C-139–C-201 and C-489–C-497 disulﬁde bonds.
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proteasome.
4. Discussion
Fig. 7 shows a predicted 3D structure of human TNSALP based on
the crystallographic analysis of human placental ALP (PLAP) [13,24].
The functional enzyme has two identical subunits, which assemble
into a dimeric structure. TNSALP has ﬁve cysteine residues (C119,
C139, C201, C489 and C480) per subunit. Their positions were well
conserved among four human ALP isozymes and other mammalian
ALPs [3,24,25]. C119 is thought to be in a free state, while C201 and
C489 form a disulﬁde bond with C139 and C497, respectively, in the
same subunit. We previously reported that TNSALP with a substitu-
tion of cysteine at position 119 by serine is indistinguishable from
the TNSALP (W) in transiently transfected cells with almost full en-
zyme activity [10], suggesting this residue does not contribute to
overall structure and function of TNSALP.
In this study we examined molecular properties of TNSALP
(C201Y) and TNSALP (C489S), which were reported in the patients
diagnosed with perinatal form of HPP [14,15]. As these TNSALP muta-
tions are severe alleles, it is reasonable to predict that the C-139–C-
201 and the C-489–C-497 disulﬁde bonds play important roles in
acquisition of structural integrity of TNSALP. This holds truth. Only a
weak enzyme activity was observed in the cells expressing TNSALP
(C201Y) or TNSALP (C489S) with a comparison to those expressing
the TNSALP (W) (Fig. 1). No activity over background levels was
detected in the cells expressing TNSALP (C201Y/C489S). Sucrose-density-gradient centrifugation analysis demonstrated that TNSALP
(C201Y) is largely present as a monomeric form in contrast to the di-
meric one of TNSALP (W) enzyme in the established cells (Fig. 4). This
ﬁnding suggests that the C-139–C-201 disulﬁde bond helps assist
monomeric TNSALP to fold into a tertiary structure, which is
competent to assemble with the counterpart subunit non-covalently.
A small fraction of TNSALP (C201Y) is able to reach the cell surface
in transiently transfected cell (Fig. 1B). This was further conﬁrmed by
PI-PLC digestion (Fig. 4B) of TNSALP (C201Y), expressed in the estab-
lished cell line, indicating that reduced cell surface appearance was
not resulted from an excess amount of the protein generated in the
transiently transfected cells, but is intrinsic property to TNSALP
(C201Y) and probably TNSALP (C489S). As TNSALP (C201Y) and
TNSALP (C489Y) have a weak ALP activity on the cell surface, it is like-
ly that a minute fraction of each TNSALP mutant becomes functional
even without a disulﬁde bonding, though the probability to acquire
proper folding and correct assembly is quite small compared with
TNSALP (W) as assessed by ALP activity (Fig. 1).
The 66 kDa form of TNSALP (C201Y) in the Tet-On cell fails to exit
from ER, as judged by its sensitivity to Endo H (Fig. 3C). We previous-
ly reported that TNSALP mutant proteins such as TNSALP (E235G),
TNSALP (D306V) and TNSALP (1559delT) are destroyed in ER associ-
ated degradation in transiently transfected cells, where these TNSALP
mutants formed high molecular mass aggregates [11,18,19]. Fig. 6
shows that TNSALP (C201Y) also undergoes polyubiquitination prior
to the degradation in proteasome, as enhanced ubiquitination and
impairment of degradation were observed in the cells treated with
LLnL and lactacystin, proteasome inhibitors. This ﬁnding excludes a
possibility that the aggregate formation occurring in the transfected
cells triggers the degradation of TNSALP mutant proteins and does
not necessarily reﬂect quality control in the ER in vivo. Defect in traf-
ﬁcking of TNSALP mutants was also reported [26,27]. Thus, some se-
vere forms of HPP can be added to a list of diseases caused by
protein misfolding [28].
PLAP has ﬁve cysteine residues at very similar positions as TNSALP
(at positions 101, 121, 183, 467 and 174). Kozlenkov et al. [29] exam-
ined the structural importance of the disulﬁde bond of PLAP by repla-
cing each cysteine residue with serine. In their study PLAP mutant
proteins were expressed as a secreted protein with a FLAG tag at its
carboxyl-terminus and puriﬁed for kinetic study. It is worth to men-
tion three relevant points. Firstly, puriﬁed PLAP (C101S) was indistin-
guishable from the wild enzyme, consistent with our ﬁnding about
TNSALP (C119S) [10], strongly indicating that this free cysteine resi-
due has only a minor role in the structure and function of both
587Y. Satou et al. / Biochimica et Biophysica Acta 1822 (2012) 581–588TNSALP and PLAP. Secondly, upon disruption of C-121–C-183
disulﬁde bond, neither PLAP (C121S) nor PLAP (C183S) was found
in the culture media. In conjunction with our present data about
TNSALP (C201Y), it is highly likely that PLAP lacking the C-121–C-
183 disulﬁde bond is also subjected to proteasomal degradation and
as a result failed to be secreted, further highlighting the structural
importance of the C-121–C-183 and the C-139–C-201 disulﬁde
bonds in PLAP and TNSALP, respectively. Finally, PLAP (C467S) and
PLAP (C474S) were puriﬁed to a homogeneity with catalytic
properties comparable to PLAP, indicating that C-467–C-474
disulﬁde bond of PLAP plays a lesser structural role than does the C-
121–C-183 disulﬁde bond. It is of interest that TNSALP (C489S) has
less than 5% of the wild-type activity and the cell surface appearance
was strongly impaired (Fig. 1), implying that unlike the counterpart
in PLAP, the C-489–C-497 disulﬁde bond has a signiﬁcant structural
role, even though both the C-489–C-497 and C-467–C-474 disulﬁde
bonds are thought to localize at the carboxyl terminus of each
isozyme.
There is no established therapeutics for HPP, however, several
groups have been challenging this inborn error of metabolism. Mar-
row cell transplantation [30,31] and treatment using Teriparatide (re-
combinant human PTH 1–34) [32] have been reported. Especially,
clinical trials using an enzyme replacement therapy are now under
the way for childhood and adult HPP (http://clinicaltrials.gov/),
where a soluble human recombinant TNSALP with a bone-targeted
motif is subcutaneously injected [33–35]. Other attempts have also
been made aiming at ex vivo gene therapy [36] or in vivo gene therapy
[37] for HPP.
In conclusion, by disrupting the two intra-chain disulﬁde bonds
we have demonstrated that the disulﬁde bonds play a key role in fold-
ing and cell surface appearance of TNSALP, providing the molecular
basis of HPP where one of the two intra-chain disulﬁde bond is miss-
ing due to the missense mutations in the TNSALP gene.Acknowledgements
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